CERVAVAC (quadrivalent HPV vaccine, India)
India's first home-made HPV vaccine, protecting against the two virus types that cause most cervical cancers and the two that cause genital warts, at a price meant for a national programme.
Overview
CERVAVAC is a quadrivalent HPV vaccine (types 6, 11, 16 and 18) developed by the Serum Institute of India with Department of Biotechnology support and produced in Hansenula polymorpha yeast. It is indicated for girls and women aged 9 to 26 against cervical, vulvar, vaginal and anal cancers and genital warts, and for boys and men aged 9 to 26 against anal cancer and genital warts; the schedule is two doses at 0 and 6 months for ages 9 to 14 and three doses (0, 2 and 6 months) for ages 15 to 26. It received Indian market authorisation in 2022 and was introduced in 2023, and published comparisons report immunogenicity non-inferior to established vaccines.
Its importance is supply and price: India records about 127,500 cervical cancer cases and 79,900 deaths a year (GLOBOCAN 2022), and vaccination depended on two imported products. A domestic vaccine, together with the IARC India evidence that a single dose protects as well as two or three, is what makes a national programme for girls aged 9 to 14 affordable; its proposed inclusion in the Universal Immunisation Programme is described in the 2026 literature as a milestone still being rolled out.
1.L1 protein particles mimic the virus shell without DNA
- Route
- Intramuscular
- Schedule
- Ages 9-14: two doses at 0 and 6 months; ages 15-26: three doses at 0, 2 and 6 months
- Monitoring
- None routine
Source: www.seruminstitute.com/product_ind_cervavac.php. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| IN | 2022 | Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26 · Market authorisation from the DCGI in 2022; introduced 2023 |
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| IN | Planned for the Universal Immunisation Programme; state programmes and private market meanwhile | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"CERVAVAC" OR ABSTRACT:"CERVAVAC" OR TITLE:"quadrivalent HPV vaccine, India" OR ABSTRACT:"quadrivalent HPV vaccine, India" OR TITLE:"qHPV vaccine Serum Institute" OR ABSTRACT:"qHPV vaccine Serum Institute" OR TITLE:"Cervavac" OR ABSTRACT:"Cervavac") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CERVAVAC (quadrivalent HPV vaccine, India), not a curated reading list.
Pages like this
not linked directly; found by shared links- TrialKEN SHE (single-dose HPV vaccine)
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), Nonavalent HPV vaccine.
- PersonPartha Basu
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
- IdeaSwitch every country to single-dose HPV vaccination and add catch-up to age 26
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care.
- IdeaEliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care.
- PersonRengaswamy Sankaranarayanan
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
- PersonJian Zhou
Shares Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.
- Key paperSwedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care.
- IdeaHPV self-testing with same-day treatment as the national cervical programme
Shares HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care, Cervical cancer.